EDP-322

EDP-322 is a first-in-class oral bicyclolide antibiotic developed for the treatment of infections caused by multidrug-resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Neisseria gonorrhoeae. It belongs to the class of bicyclic macrolides (bicyclolides), which are structurally related to erythromycin. EDP-322 has demonstrated potent in vitro activity against N. gonorrhoeae, including strains resistant to azithromycin, cefixime, ceftriaxone, spectinomycin, ampicillin, tetracycline, and ciprofloxacin. Its mechanism of action is presumed to be similar to other macrolide antibiotics—binding to the bacterial 50S ribosomal subunit and inhibiting protein synthesis—though specific molecular targets have not been explicitly detailed in available literature. The drug was studied as a potential option for treating infections where resistance limits current therapies[1][2][3][5][8].